Physician profile
John Onufer
NPI 1023084100
$7,266.44
in general payments reported to CMS, 2019-2025
32 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $1,065 · 2021: $481 · 2022: $2,043 · 2023: $1,098 · 2024: $858 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,187.78 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Bodyguardian, General - Tachy |
| Abbott Laboratories | $1,445.32 | 2019-2024 | Perclose Proglide, Amplatzer Amulet |
| Novartis Pharmaceuticals Corporation | $586.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.96 | 2020-2025 | Jardiance |
| Pfizer INC. | $320.90 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $194.11 | 2019-2024 | Xarelto |
| Cardiva Medical, INC. | $184.76 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Abiomed | $180.33 | 2020-2022 | |
| Biosense Webster, INC. | $176.19 | 2021-2024 | Carto 3 |
| Amgen INC. | $171.87 | 2019-2024 | Repatha |
| Novo Nordisk INC | $162.94 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $150.50 | 2023 | Diamondtemp Bidirectional Ablation Catheter |
| Impulse Dynamics (USA) INC. | $146.65 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $143.48 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $141.25 | 2023 | Sapien 3 Ultra Resilia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $106.19 | 2021-2024 | Eliquis, Camzyos |
| Medtronic Vascular, INC. | $61.80 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $61.18 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $56.21 | 2024-2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $50.30 | 2024 | Uptravi, Opsumit |
| Genzyme Corporation | $46.22 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $30.85 | 2021-2022 | |
| Smith+Nephew, INC. | $29.59 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $25.96 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $22.67 | 2025 | Assure Wcd |
| Scpharmaceuticals INC. | $22.10 | 2025 | |
| Stryker Corporation | $21.72 | 2023 | N/A |
| Irhythm Technologies, INC. | $20.04 | 2024 | Zio Monitor, Zio Xt Patch |
| Acist Medical Systems, INC. | $18.54 | 2022 | |
| Terumo Medical Corporation | $14.80 | 2023 | Glidewire, Heartrail |
| Elutia, INC. | $14.60 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Onufer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.